S&P 500   4,639.18 (+1.58%)
DOW   34,912.44 (+1.24%)
QQQ   398.52 (+1.19%)
AAPL   169.27 (+2.40%)
MSFT   334.87 (+1.29%)
FB   325.88 (+0.44%)
GOOGL   2,910.47 (+2.56%)
AMZN   3,535.15 (+0.80%)
TSLA   1,155.04 (+0.90%)
NVDA   329.78 (+0.92%)
BABA   127.60 (+0.05%)
NIO   40.44 (+3.35%)
CGC   10.84 (+1.21%)
AMD   158.80 (+0.27%)
GE   95.60 (+0.64%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.34 (+5.99%)
DIS   147.28 (+1.64%)
ACB   6.47 (+0.78%)
PFE   53.79 (+0.11%)
AMC   34.11 (+0.50%)
BA   199.20 (+0.68%)
S&P 500   4,639.18 (+1.58%)
DOW   34,912.44 (+1.24%)
QQQ   398.52 (+1.19%)
AAPL   169.27 (+2.40%)
MSFT   334.87 (+1.29%)
FB   325.88 (+0.44%)
GOOGL   2,910.47 (+2.56%)
AMZN   3,535.15 (+0.80%)
TSLA   1,155.04 (+0.90%)
NVDA   329.78 (+0.92%)
BABA   127.60 (+0.05%)
NIO   40.44 (+3.35%)
CGC   10.84 (+1.21%)
AMD   158.80 (+0.27%)
GE   95.60 (+0.64%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.34 (+5.99%)
DIS   147.28 (+1.64%)
ACB   6.47 (+0.78%)
PFE   53.79 (+0.11%)
AMC   34.11 (+0.50%)
BA   199.20 (+0.68%)
S&P 500   4,639.18 (+1.58%)
DOW   34,912.44 (+1.24%)
QQQ   398.52 (+1.19%)
AAPL   169.27 (+2.40%)
MSFT   334.87 (+1.29%)
FB   325.88 (+0.44%)
GOOGL   2,910.47 (+2.56%)
AMZN   3,535.15 (+0.80%)
TSLA   1,155.04 (+0.90%)
NVDA   329.78 (+0.92%)
BABA   127.60 (+0.05%)
NIO   40.44 (+3.35%)
CGC   10.84 (+1.21%)
AMD   158.80 (+0.27%)
GE   95.60 (+0.64%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.34 (+5.99%)
DIS   147.28 (+1.64%)
ACB   6.47 (+0.78%)
PFE   53.79 (+0.11%)
AMC   34.11 (+0.50%)
BA   199.20 (+0.68%)
S&P 500   4,639.18 (+1.58%)
DOW   34,912.44 (+1.24%)
QQQ   398.52 (+1.19%)
AAPL   169.27 (+2.40%)
MSFT   334.87 (+1.29%)
FB   325.88 (+0.44%)
GOOGL   2,910.47 (+2.56%)
AMZN   3,535.15 (+0.80%)
TSLA   1,155.04 (+0.90%)
NVDA   329.78 (+0.92%)
BABA   127.60 (+0.05%)
NIO   40.44 (+3.35%)
CGC   10.84 (+1.21%)
AMD   158.80 (+0.27%)
GE   95.60 (+0.64%)
MU   88.56 (+5.43%)
T   22.89 (+0.26%)
F   20.34 (+5.99%)
DIS   147.28 (+1.64%)
ACB   6.47 (+0.78%)
PFE   53.79 (+0.11%)
AMC   34.11 (+0.50%)
BA   199.20 (+0.68%)
NASDAQ:IMMP

Immutep Stock Forecast, Price & News

$3.48
+0.05 (+1.46%)
(As of 12/1/2021 10:50 AM ET)
Add
Compare
Today's Range
$3.43
$3.48
50-Day Range
$3.28
$4.81
52-Week Range
$1.88
$7.95
Volume
947 shs
Average Volume
1.13 million shs
Market Capitalization
$297.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
30 days | 90 days | 365 days | Advanced Chart
Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.


Immutep logo

About Immutep

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Headlines

Short Interest in Immutep Limited (NASDAQ:IMMP) Rises By 110.4%
November 30, 2021 |  americanbankingnews.com
Immutep Limited (NASDAQ:IMMP) Short Interest Up 83.0% in October
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMP
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.96 million
Book Value
$0.72 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$297.15 million
Optionable
Not Optionable

Company Calendar

Today
12/01/2021
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

966th out of 1,390 stocks

Pharmaceutical Preparations Industry

452nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Immutep (NASDAQ:IMMP) Frequently Asked Questions

Is Immutep a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep
or view top-rated stocks.

How has Immutep's stock price been impacted by Coronavirus (COVID-19)?

Immutep's stock was trading at $2.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMMP shares have increased by 63.4% and is now trading at $3.48.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Immutep?

Immutep saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 213,300 shares, an increase of 110.4% from the October 31st total of 101,400 shares. Based on an average trading volume of 373,700 shares, the short-interest ratio is presently 0.6 days.
View Immutep's Short Interest
.

What price target have analysts set for IMMP?

2 brokers have issued 12 month price objectives for Immutep's shares. Their forecasts range from $8.00 to $9.00. On average, they expect Immutep's stock price to reach $8.43 in the next year. This suggests a possible upside of 142.3% from the stock's current price.
View analysts' price targets for Immutep
or view top-rated stocks among Wall Street analysts.

Who are Immutep's key executives?

Immutep's management team includes the following people:
  • Marc Voigt, Chief Executive Officer, CFO & Executive Director
  • Deanne Miller, COO, Secretary & General Counsel
  • David Fang, Finance Director & Assistant Secretary
  • Frédéric Triebel, Chief Scientific & Medical Officer
  • Christian Mueller, Vice President-Strategic Development

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by a variety of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.49%), Morgan Stanley (1.46%), Renaissance Technologies LLC (0.26%), Verition Fund Management LLC (0.17%), Saturna Capital CORP (0.11%) and Belvedere Trading LLC (0.04%).

Which major investors are selling Immutep stock?

IMMP stock was sold by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Millennium Management LLC, and Morgan Stanley.

Which major investors are buying Immutep stock?

IMMP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Belvedere Trading LLC, Toroso Investments LLC, Captrust Financial Advisors, Beirne Wealth Consulting Services LLC, Lindbrook Capital LLC, Jump Financial LLC, and Geode Capital Management LLC.

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $3.48.

How much money does Immutep make?

Immutep has a market capitalization of $297.15 million and generates $2.96 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

Where are Immutep's headquarters?

Immutep is headquartered at LEVEL 12 95 PITT STREET, SYDNEY C3, 2000.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at (128) 315-7003, via email at [email protected], or via fax at 61-2-8569-1880.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.